DSY.PA - Dassault Systèmes SE

Paris - Paris Delayed Price. Currency in EUR
134.55
-1.35 (-0.99%)
As of 12:46PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close135.90
Open135.65
Bid0.00 x 0
Ask0.00 x 0
Day's Range134.10 - 135.65
52 Week Range96.02 - 147.20
Volume79,383
Avg. Volume294,519
Market Cap34.85B
Beta (3Y Monthly)0.67
PE Ratio (TTM)59.27
EPS (TTM)2.27
Earnings DateJul 24, 2019
Forward Dividend & Yield0.65 (0.48%)
Ex-Dividend Date2019-05-29
1y Target Est126.17
  • GlobeNewswire5 days ago

    Dassault Systèmes : Half-year statement of the Liquidity contract between Dassault Systèmes and Oddo BHF SCA

    Half-year statement of the Liquidity contract between Dassault Systèmes and Oddo BHF SCA Vélizy-Villacoublay, France – July 17, 2019 — Dassault Systèmes (Euronext Paris:.

  • GlobeNewswire5 days ago

    Dassault Systèmes : Update of the Liquidity contract

    Update of the liquidity contract Vélizy-Villacoublay (France) – July 17, 2019 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA), “The 3DEXPERIENCE Company”, announces that.

  • GlobeNewswire11 days ago

    Dassault Systemes to Publish its Second Quarter 2019 Results, Webcast and Conference Call on July 24th 2019

    DASSAULT SYSTEMES TO PUBLISHITS SECOND QUARTER 2019 RESULTS,WEBCAST AND CONFERENCE CALL ON JULY 24th 2019     VÉLIZY-VILLACOUBLAY, France — July 11th, 2019 — Dassault.

  • GlobeNewswire14 days ago

    Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of June 30, 2019

    Declaration of the number of outstanding shares and voting rightsas of June 30, 2019 Vélizy-Villacoublay (France) July 8, 2019 – Dassault Systèmes (Euronext Paris: #13065,.

  • What Does Dassault Systèmes SE’s (EPA:DSY) 13% ROCE Say About The Business?
    Simply Wall St.19 days ago

    What Does Dassault Systèmes SE’s (EPA:DSY) 13% ROCE Say About The Business?

    Today we'll evaluate Dassault Systèmes SE (EPA:DSY) to determine whether it could have potential as an investment...

  • Business Wire21 days ago

    Dassault Systèmes Named Key Supplier by Groupe PSA for its Digital Transformation

    .@GroupePSA names @Dassault3DS preferred digital partner for its digital transformation #3DEXPERIENCE #mobility

  • GlobeNewswirelast month

    Dassault Systèmes: Dassault Systèmes Continues to Demonstrate Its Commitment to Life Sciences for Patient Experience by Investing in BioSerenity

    Dassault Systèmes Continues to Demonstrate Its Commitment to Life Sciences for Patient Experience by Investing in BioSerenity BioSerenity, developer of solutions dedicated.

  • Business Wirelast month

    Dassault Systèmes Continues to Demonstrate Its Commitment to Life Sciences for Patient Experience by Investing in BioSerenity

    .@Dassault3DS invests in @BioSerenity to reinforce its commitment to innovation in #telemedicine #3DEXPERIENCE #digitalhealth #telehealth

  • Business Wirelast month

    Dassault Systèmes at the International Paris Air Show: Reinventing the Sky with the Virtual World

    .@Dassault3DS at the @parisairshow to show how #aerospace innovators are reinventing the sky with the virtual world #3DEXPERIENCE

  • TheStreet.comlast month

    Medidata Solutions Dips After $5.8 Billion Sale to France's Dassault Systemes

    shares traded lower Wednesday after it agreed a takeover offer from France's Dassault Systemes SE at a discount to its current market value. Dassault said it would pay $92.25 for each Medidata share in a deal that values the New York-based group at $5.8 billion. "Today marks a significant milestone for the Life Sciences industry and the value of the virtual world to address the complexity of developing personalized medicine and patient-centric experiences," said Dassault CEO Bernard Charles.

  • Dassault to Buy Medidata in $5.7 Billion Shift to Health
    Bloomberglast month

    Dassault to Buy Medidata in $5.7 Billion Shift to Health

    (Bloomberg) -- French technology company Dassault Systemes SE agreed to buy Medidata Solutions Inc., a software firm that analyzes clinical trials, for $5.7 billion to bolster its offerings to the pharmaceutical industry.The record deal will allow Dassault to offer drugmakers a complete set of services and ride a shift toward personalized medicine, in which research and tools are tailored to individual patient profiles, generating the need to analyze vast amounts of data.Health is becoming a crucial market for Dassault, which also creates 3D design software, said Pascal Daloz, the company’s chief financial officer. Medidata offers clients wearable sensors that help track patients’ health in real life and biomarker analysis to select which ones may best respond to drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology.“This is by far the largest acquisition we’ve ever made,” Daloz said on a conference call, highlighting Dassault’s interest in the health market.Drugmakers’ CostsThe all-cash transaction values Medidata at $92.25 a share -- 17% more than Medidata’s closing price on April 18, the last trading day before Bloomberg reported Dassault’s interest in the New York-based company. Medidata shares were down 3.5% to $91.45 at 9:59 a.m. in New York. Dassault fell 1.5% to 134.45 euros in Paris.The deal is expected to close in the final quarter of 2019 and start boosting earnings as early as 2020, the companies said in a statement.Drugmakers faced with rising development costs are outsourcing many parts of their research and development efforts, using specialized providers of services and technology.Medidata counts most of the biggest drug companies in the world as customers, according to supply-chain data compiled by Bloomberg. It provides a cloud-based subscription service that helps medical device, diagnostic and pharmaceutical companies manage and analyze clinical trials. Its revenue more than doubled from 2013 to 2018, when it brought in $635.7 million.Dassault, with a market value of 36 billion euros ($41 billion), offers software and services for industries ranging from aerospace and defense to consumer goods. The life sciences business counts many major pharma companies among its clients.The planned acquisition, endorsed by both boards, marks the first time the French company has resorted to external funding, according to Daloz. Dassault will finance the takeover with a 1 billion-euro loan, a 3 billion-euro bridge-to-loan facility and available cash.(Updates with Dassault shares in sixth paragraph.)\--With assistance from Liana Baker, Geraldine Amiel and Marie Mawad.To contact the reporters on this story: Ed Hammond in New York at ehammond12@bloomberg.net;Ruth David in London at rdavid9@bloomberg.net;Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.netTo contact the editors responsible for this story: Elizabeth Fournier at efournier5@bloomberg.net, ;Giles Turner at gturner35@bloomberg.net, Jeff Sutherland, Thomas MulierFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • TheStreet.comlast month

    Tesla, Medidata, United Tech-Raytheon, Dave & Buster's - 5 Things You Must Know

    U.S. stock futures declined on Wednesday as optimism faded over a near-term trade deal between Washington and Beijing and Wall Street awaited a reading on U.S. inflation. Contracts tied to the Dow Jones Industrial Average fell 71 points, futures for the S&P 500 declined 8.65 points, and Nasdaq futures were down 37 points. Donald Trump said Tuesday he wouldn't agree to a trade deal unless China agrees to four or five "major points" that the president didn't specify.

  • Dassault to Buy Medidata in $5.7 Billion Health Data Push
    Bloomberglast month

    Dassault to Buy Medidata in $5.7 Billion Health Data Push

    (Bloomberg) -- Dassault Systemes SE, a maker of industrial design software, agreed to buy Medidata Solutions Inc. for $5.7 billion to gain a foothold in the fast-growing market for clinical trial technology.The deal pushes the French company further beyond its design roots into data processing and business analysis. Medidata’s software analyzes pharmaceutical and biotech trials for some of the world’s biggest drugmakers including Sanofi SA, Pfizer Inc. and AstraZeneca Plc.“This is by far the largest acquisition we’ve ever made,” Pascal Daloz, chief financial officer of Dassault Systemes, said on a conference call. He said health is becoming a crucial market for the company, whose customers are mostly in aerospace, defense and consumer goods.The all-cash deal values New York-based Medidata at $92.25 a share, 17% above its closing price on April 18, the last trading day before Bloomberg reported Dassault Systemes’ interest in the company. Medidata stock fell 4.4% to $90.60 in premarket trading.Shares in Dassault Systemes, which has a market value of 36 billion euros ($41 billion) and annual sales of 3.5 billion euros last year, fell as much as 3% before recouping some of the decline to trade down 1% at 11:31 a.m. in Paris.Personalized MedicineMedidata offers clients wearable sensors that help track patient health and biomarker analysis to select which patients may best respond to certain drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology, as the healthcare industry shifts towards personalized medicine and the targeting of individual patient profiles.President Donald Trump’s protectionist trade agenda hasn’t reduced the appetite of European companies for U.S. takeovers. In fact their appeal has been growing, potentially turning the tables after years in which Europe was mostly a target for U.S. acquirers.French advertising group Publicis Groupe SA announced its biggest ever takeover in April, a $4.4 billion deal for U.S.-based Alliance Data Systems Corp.’s digital marketing unit Epsilon.The Medidata deal is expected to close in the final quarter of 2019 and start boosting earnings as early as 2020, the companies said in a statement. Dassault Systemes will finance it with a 1 billion-euro loan, a 3 billion-euro bridge-to-loan facility and available cash. It’s the first time the French company has resorted to external funding, Daloz said.(Adds Medidata premarket share price in fourth paragraph.)\--With assistance from Liana Baker, Manuel Baigorri, Ruth David, Ed Hammond and Marthe Fourcade.To contact the reporters on this story: Marie Mawad in Paris at mmawad1@bloomberg.net;Geraldine Amiel in Paris at gamiel@bloomberg.netTo contact the editors responsible for this story: Giles Turner at gturner35@bloomberg.net, Thomas Pfeiffer, Frank ConnellyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • MarketWatchlast month

    Dassault offers to buy Medidata in $5.8 billion deal

    Dassault Systemes SE on Wednesday announced a definite agreement for U.S. technology group Medidata Solutions Inc. , in an agreement valued at $5.8 billion. Under terms of the all-cash deal, the French technology group will offer $92.25 for each share of Medidata, whose shares closed at $94.75 a share on Tuesday. The transaction was unanimously approved by the boards of directors of both companies.

  • Reuterslast month

    European shares retreat from 3-week highs on U.S.-China trade jitters

    European shares pulled back from three-week highs on Wednesday after the United States toughened its stance on trade with China and data from Beijing showed factory inflation slowed in May, deepening fears of a global economic slowdown. President Donald Trump said on Tuesday he was holding up a trade deal with China and had no interest in moving ahead unless Beijing agrees to four or five "major points" which he did not specify. Also weighing down the sector was a 1.2% fall in shares of Dassault Systemes after the French technology company agreed to buy Medidata Solutions, a U.S. software company involved in the sphere of clinical trials, in a deal worth $5.8 billion.

  • Bloomberglast month

    Dassault Agrees to Buy Medidata in $5.8 Billion Health Deal

    The all-cash deal, which will bolster Dassault’s life-science unit, values Medidata at $92.25 a share. Healthcare has become a core market for Dassault, said Pascal Daloz, Chief Financial Officer, in a call with reporters.

  • Reuterslast month

    UPDATE 3-Dassault Systemes targets life sciences with $5.8 bln Medidata deal

    France's Dassault Systemes moved to build up its life sciences presence with a $5.8 billion cash deal to buy Medidata Solutions, a U.S. firm focused on clinical trials. Dassault Systemes has been doing deals to diversify its technology and software businesses further and its agreed acquisition of Medidata, its largest, follows its purchases of companies including Trace Software and Argosim. Medidata has a market capitalisation of around $5.9 billion, Refinitiv Eikon data shows, while Dassault has a stock market value of around 36 billion euros ($41 billion).

  • Dassault Systemes targets life sciences with $5.8 billion Medidata deal
    Reuterslast month

    Dassault Systemes targets life sciences with $5.8 billion Medidata deal

    France's Dassault Systemes moved to build up its life sciences presence with a $5.8 billion cash deal to buy Medidata Solutions, a U.S. firm focused on clinical trials. Dassault Systemes has been doing deals to diversify its technology and software businesses further and its agreed acquisition of Medidata, its largest, follows its purchases of companies including Trace Software and Argosim. Medidata has a market capitalisation of around $5.9 billion, Refinitiv Eikon data shows, while Dassault has a stock market value of around 36 billion euros ($41 billion).

  • GlobeNewswirelast month

    Dassault Systèmes and Medidata Solutions To Join Forces To Accelerate the Life Sciences Industry Innovation For Patient-Centric Experience Through End-to-End Collaborative Platform

    Vélizy-Villacoublay, France and New York — June 12, 2019 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA) and Medidata Solutions, Inc. (MDSO), leader of the digital transformation of the Life Sciences industry for clinical development, commercial, and real-world data intelligence, today announced the signing of a definitive agreement for Dassault Systèmes to acquire Medidata in an all-cash transaction at a price of $ 92.25 per share of Medidata, representing an enterprise value of $5.8 billion. The transaction was unanimously approved by the Boards of Directors of both companies.

  • GlobeNewswirelast month

    Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of May 31, 2019

    Declaration of the number of outstanding shares and voting rightsas of May 31, 2019 Vélizy-Villacoublay (France) June 7, 2019 – Dassault Systèmes (Euronext Paris: #13065,.